Innovative Targeted and Immune-Mediated Cancer Therapies

Pipeline

Developing first-in-class oral drug therapeutics with broad potential benefit for cancer patients

Learn more

Science

Thoughtful exploration of new and validated pathways to discover and develop novel therapeutics

Learn more

News

June 20, 2024
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm

June 18, 2024
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

June 7, 2024
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Events

Thursday, June 20TH, 2024 at 8:30 AM Eastern
Amezalpat (TPST-1120) Global Randomized Phase 1b/2 Combination Study Update Call
Listen: Webcast
Download: Presentation [pdf]

Wednesday, June 5TH, 2024 at 4:00 PM Eastern
Jefferies Global Healthcare Conference
Listen: Webcast

Wednesday, May 29TH, 2024 at 2:00 PM Eastern
TD Cowen's 5th Annual Oncology Innovation Summit
Listen: Webcast

Wednesday, October 11TH, 2023 at 8:30 AM Eastern
TPST-1120 Global Randomized Phase 1b/2 Combination Study Data Call
Listen: Webcast
Download: Presentation [pdf]